[1]
Löscher W.: New visions in the pharmacology of anticonvulsion. Eur. J.
Pharmacol 1998; 342: 1–13.
[2]
Rogawski M. A.: Brivaracetam: a rational drug discovery success story.
Br J Pharmacol 2008; 154: 1555–1557.
[3]
Łuszczki J.J.: Third-generation antiepileptic drugs: mechanisms of
action, pharmacokonetics and interactions. Pharmacological Reports
2009; 61: 197–216
[4]
Sargentini-Maier M. L., Rolan P., Connell J., et al.: The pharmacokinetics,
CNS pharmacodynamics and adverse profile of bivaracetam after single
increasing oral doses in healthy males., Br J Clin Pharmacol 2007; 63:
680–688.
[5]
Bialer M., Johannessen S.I, Kupferberg H.J., et al.: Progress report on
new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT
V). Epilepsy Res 2001; 43: 11–58.
[6]
Bialer M.: New antiepileptic drugs that are second generation to existing
antiepileptic drugs. Expert Opin Investig Drugs 2006; 15: 637–647.
[7]
Bennet B., Matagne A., Michel P., et al.: Seletracetam (UCB 44212).
Neurotherapeutics 2007; 4: 117–122.
[8]
Matagne A., Margineanu D.G., Potschka H., et al.: Profile of the new
pyrrolidone derivative seletracetam (ucb 44212) in animal models of
epilepsy. Eur. J Pharmacol 2009; 614: 30–37.
[9]
Rogawski M. A.: Brivaracetam: a rational drug discovery success story.
Br J Pharmacol 2008; 154: 1555–1557.
[10]
Rogawski M. A.: Diverse mechanisms of antiepileptic drugs in the
development pipeline. Epilepsy Res 2006; 69: 273–294.
[11]
Bialer M., Johannessen S. I., Levy R. H., et al: Progress report on new
antiepileptic drugs: A summary of the Ninth Eilat Conference (EILAT IX).
Epilepsy Res 2009; 83: 1–43.
[12]
Pollard J.R., French J.: Antiepileptic drugs in development., Lancet
Neurol 2006; 5: 1064–1067.
[13]
Bialer M., Johannessen S.I., Kupferberg H.J., et al.: Progress report on
new antiepileptic drugs: a summary of the Eigth Eilat Conference (EILAT
VIII). Epilepsy Res 2007; 73: 1–52.
[14]
Lynch B.A., Lambeng N., Nocka K., et al.: The synaptic vesicle protein
SV2A is the binding site for the antiepileptic drug levetiracetam. 2004;
Proc. Natl. Acad. Sci. U.S.A, 2004; 101: 9861– 9866.
[15]
Hamann M., Sander S., Richter A.: Brivaracetam and seletracetam,
two new SV2A ligands, improve paroxysmal dystonia in the dtsz mutant
hamster. Eur. J Pharmacol 2008; 601: 99–102.
[16]
Matagne A., Kenda B., Michel P., et al.: Ucb 34714, a new pyrrolidine
derivative , suppresses seizures epileptogenesis in animal models of
chronic epilepsy in vivo. Epilepsia 2003; 44: 53–54
[17]
Wasterlain C., Suchomelova L., Matagne A., et al.: Brivaracetam is
a potent anticonvulsant in experimental status epilepticus. Epilepsia
2005; 46: 219.
[18]
Bialer M., Johannessen S.I, Kupferbergb H.J., et al.: Progress report on
new antiepileptic drugs: a summary of the Seventh Eilat Conference
(EILAT VII). Epilepsy Res 2004; 61: 1–48.
[19]
Sargentini-Maier M.L, Espie P., Coquette A., et al.: Pharmacokonetics
and metabolism of 14C- briveracetam, a novel SV2A ligand, in healthy
subjects. Drug Metab Dispos 2008; 36: 36–45.
[20]
Otoul C., von Rosenstiel P., Stockis A.: Evaluation of the pharmacokonetic
interaction of brivaracetam on other antiepileptic drugs in adults with
partial-onset seizures. Epilepsia 2007; 48: 334.
[21]
Van Rosenstiel P: Brivaracetam (UCB 34714). Neurotherapeutics 2007;
4: 84–87.
[22]
Kastelejin-Nolst Trenite, D.G., Genton P., et al: Evaluation of briveracetam,
a novel SV2A ligand, in the photosensitivity model. Neurology 2007; 69:
1027–1034.
[23]
Brodsky A., Costantini C., von Rosenstiel P.: Safety and tolerability
of brivaracetam (UCB 34714) as adjunctive treatment in adults with
refractory partial-onset seizures. Epilepsia 2007; 48: 342.
[24]
Van Paesschen W., Hirsch E., Johnson M., et al.: Efficacy and tolerability
of adjunctive brivaracetam in adults with uncontrolled partial-onset
seizures: A phase II b, randomized, controlled trial. Epilepsia 2012; 10:
1528–1167.
Scholar Google
PubMed